Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 23.8 | 55.3 | 31.5 | 32.7 | 29.1 | 8.3 | 7.5 |
| Operating profit | $m | -1,285 | -1,366 | |||||
| Net profit | $m | -809 | -845 | -1,009 | 4,349 | -172 | -300 | -266 |
| EPS reported | $ | -0.43 | -0.44 | |||||
| Operating cashflow per share | $ | -1.08 | -1.12 | |||||
| Capex per share | $ | 0.01 | 0.01 | |||||
| FCF per share | $ | -1.09 | -1.13 | |||||
| Free cash flow | $m | -759 | -814 | |||||
| Net debt | $m | -4,285 | -3,842 | |||||
| Book value equity | $m | 4,527 | 4,231 | |||||
| Book value per share | $ | 6.52 | 5.87 | |||||
| Number of shares | m | 693.86 | 720.78 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 4.25 | 6.10 | |||||
| P/S LTM | x | 2,326.88 | 3,425.96 | |||||
| P/FCF LTM | x | -25.34 | -31.70 | |||||
| EV/EBITDA LTM | x | -68.54 | -78.06 | |||||
| EV/Sales LTM | x | 2,167.60 | 2,915.86 | |||||
| Earnings Yield LTM | % | -1.56% | -1.03% | |||||
| FCF Yield | % | -3.95% | -3.15% | |||||
| Quality | ||||||||
| ROE | % | -6.62% | -6.12% | |||||
| ROIC | % | -23.55% | -27.14% | |||||
| Operating margin | % | -15560.6% | -18140.9% | |||||
| Gross margin | % | 84.44% | 81.21% | |||||
| FCF/Sales | % | -9183.5% | -10806.6% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -71.57% | -67.58% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -7.06 | -7.60 | |||||
| Net Debt/EBITDA | x | 5.04 | 4.06 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -22.29% | -14.89% | |||||
| Net debt/Equity | x | -0.95 | -0.91 | |||||
| Gross debt/equity | x | 0.02 | 0.03 | |||||
ETFs that hold Roivant Sciences
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Invesco S&P MidCap Momentum ETF | XMMO | 3 | 3.45% |
| Alpha Architect US Equity 4 ETF | AAUB | 7 | 2.70% |
| Invesco Dorsey Wright Healthcare Momentum ETF | PTH | 6 | 3.70% |
| Adaptiv Select ETF | ADPV | 3 | 4.79% |
| Invesco Nasdaq Biotechnology ETF | IBBQ | 10 | 1.71% |
Funds with Roivant Sciences among their ten largest holdings, largest fund first.
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Invesco S&P MidCap Momentum ETF | XMMO | 3 | 3.45% |
| Alpha Architect US Equity 4 ETF | AAUB | 7 | 2.70% |
| Invesco Dorsey Wright Healthcare Momentum ETF | PTH | 6 | 3.70% |
| Adaptiv Select ETF | ADPV | 3 | 4.79% |
| Invesco Nasdaq Biotechnology ETF | IBBQ | 10 | 1.71% |
Funds with Roivant Sciences among their ten largest holdings, largest fund first.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free